To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.
February 8 – 9, 2016 | Berlin, Germany | World ADC
February 8th and 9th, 2016, Xentech will attend to the World ADC conferences in Berlin. The event highlights all aspect of Antibody Drug Conjugate drug development from discovery, preclinical, clinical and marketisation. Two members of our scientific team will attend to this 6th edition of Wordl ADC. Come to see us!
Contract Research Organization
XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....